|
Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. |
|
|
Honoraria - Roche; Takeda |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Novartis; Roche; Spectrum Pharmaceuticals |
Research Funding - Amgen; Roche; Spectrum Pharmaceuticals |
Travel, Accommodations, Expenses - Amgen; Roche |
|
Konstantinos Christofyllakis |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Roche Pharma AG |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Janssen; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Janssen; Pfizer |
|
|
Other Relationship - Medupdate |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Abbvie; Janssen-Cilag; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Gilead Sciences; Janssen; Roche |
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen; Roche |
Speakers' Bureau - Abbvie; Gilead Sciences; Janssen; Roche |
Research Funding - Abbvie; Gilead Sciences; Janssen; Roche |
Travel, Accommodations, Expenses - Janssen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Bracco Diagnostics |
Research Funding - Bracco Diagnostics; Siemens |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Siemens Healthcare Diagnostics |
Patents, Royalties, Other Intellectual Property - University Hospital Regensburg (Inst) |
|
|
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
Consulting or Advisory Role - Gilead Sciences; Roche Pharma AG |
Travel, Accommodations, Expenses - Janssen; Takeda |